CyBorD plus Daratumumab for kidney disease caused by abnormal proteins
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of four drugs (CyBorD plus daratumumab) to treat kidney damage caused by abnormal proteins (monoclonal gammopathy). It aims to improve kidney function and reduce protein levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have a kidney biopsy showing damage from abnormal proteins, or certain signs of kidney disease related to multiple myeloma.
- Your kidney function is moderately to severely reduced (eGFR below 40).
- You have measurable abnormal proteins in your blood or urine.
- You have not had prior treatment for the plasma cell condition causing the kidney problem.
- You are willing to use effective contraception if you are of childbearing potential.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for newly diagnosed multiple myeloma patients who are not eligible for or have delayed stem cell transplant. One group gets elranatamab plus a light version of RVd (lenalidomide, bortezomib, dexamethasone), and the other gets daratumumab plus the same light RVd. The goal is to find which combination works better.
This trial tests a combination of four medications (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) for people with monoclonal immunoglobulin deposition disease (MIDD), a condition where abnormal proteins build up in organs. The goal is to see if this treatment can help without prior harsh therapies.
This pilot study tests a combination of four drugs (daratumumab, cyclophosphamide, bortezomib, and dexamethasone, known as Dara-CyBorD) in people newly diagnosed with multiple myeloma who also have kidney problems. The goal is to see if this treatment is safe and effective for this specific group.
This trial tests a combination of the drugs daratumumab, carfilzomib, lenalidomide, and dexamethasone given before and after a stem cell transplant for people with ultra high-risk multiple myeloma. The goal is to see if this regimen is safe and more effective than standard treatments.
This trial tests a new drug (JNJ-79635322) combined with other treatments like daratumumab or pomalidomide for people with multiple myeloma. It aims to see if these combinations are safe and effective for newly diagnosed or previously treated patients.
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.